Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

This open-label, phase I/II study investigated the safety and efficacy of epratuzumab, a humanised anti-CD22 monoclonal antibody, in the treatment of patients with active primary Sjögren's syndrome (pSS). Sixteen Caucasian patients (14 females/2 males, 33–72 years) were to receive 4 infusions o...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Steinfeld, Serge D, Tant, Laure, Burmester, Gerd R, Teoh, Nick KW, Wegener, William A, Goldenberg, David M, Pradier, Olivier
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2006
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1779377/
https://ncbi.nlm.nih.gov/pubmed/16859536
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/ar2018
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky